August 16, 2021
Reminder: Request Prior Authorization for Synagis
Respiratory syncytial virus (RSV) cases usually begin to be reported in the fall and taper off in the spring. According to the American Academy of Pediatrics (AAP), it isn’t know if RSV cases will increase during the fall and into winter, and it is not clear how long the RSV cases will continue into 2022. The AAP supports the recommendation for use of palivizumab, Synagis, in patients who meet current eligibility requirements.
In compliance with the AAP recommendations Health Partners Plans request that providers send prior authorization requests to the pharmacy for any member that they feel requires Synagis. All requests will be reviewed on a case by case basis in accordance with the AAP guidance.
If you have any questions, please contact the Provider Services Helpline at 1-888-991-9023.